Director Paul Sagan buys 31,620 MRNA shares at $31.76 as stock down -81.8% from 52-week high, -23.0% in 30 days.
Director Paul Sagan purchased 31,620 shares of Moderna at $31.76 on 2025-03-03, increasing his holdings from 280,407 to 312,027 shares. The transaction occurs in the context of significant recent weakness: the stock has fallen 81.8% from its 52-week high of $166.61 and declined 23.0% over the prior 30 days, closing today at $30.37. Moderna's fundamentals deteriorated substantially, with annual revenue declining 52.8% year-over-year and the company posting full-year negative net income, though the most recent quarter generated $13.0M in net income. The purchase represents an open-market acquisition by a director during a period of compressed valuation relative to the 52-week range, coinciding with a revenue-driven profitability reset in the business.